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Concerns about environmental substances
with hormonal actions have generated scien-
tific debate about the risks they pose for
human and wildlife health. At issue are both
the degree to which low potency may limit
hormonal effects (1,2) and the difficulty of
assigning potencies to compounds with life
stage-, cell-, and gene-specific effects (3–6).
Evaluating risk requires an accurate assess-
ment of the relation between in vitro and ani-
mal tests of endocrine action and human
responses. This task is daunting for many
environmental substances, as the timing and
quantity of human exposure are often uncer-
tain, and suspected toxicity generally
precludes their use in clinical trials. 
The phytoestrogens, naturally occurring
substances with estrogenic actions, provide
an opportunity to examine these relation-
ships more fully. Phytoestrogens exhibit a
number of actions that have the potential to
alter basic reproductive and developmental
processes but also exhibit many potentially
beneficial actions (2,7). Phytoestrogen
actions and dose–response relationships have
been assessed in both in vitro and in vivo
studies and can be compared to human clini-
cal and epidemiologic studies. Phytoestrogen
exposures have been quantified for human
subjects in a number of studies, and some
pharmacokinetic data also are available. 
This review article represents a first
attempt to compile animal and human data
on biologic effects and exposure levels of
phytoestrogens in order to identify areas of
research in which direct species comparisons
can be made. In vitro and in vivo assays of
phytoestrogen action and potency are
reviewed and compared to actions,
dose–response relationships, and estimates of
exposure in human subjects. 
Types of Phytoestrogens 
and Dietary Sources
A phytoestrogen is defined as any plant
compound structurally and/or functionally
similar to ovarian and placental estrogens
and their active metabolites. This definition
includes compounds with agonistic, partial
agonistic, and antagonistic interactions with
estrogen receptors (ERs) and other targets
of estrogenic steroids involved in estrogen
transport, synthesis, and metabolism.
Functions affected by phytoestrogens
include the regulation of ovarian cycles and
estrus in female mammals and the promo-
tion of growth, differentiation, and physio-
logic activities of the female genital tract,
pituitary, breast, and many other organs
and tissues in both sexes. Additional end
points may include induction of RNA–
protein synthesis and prolactin (PRL) secre-
tion; prevention of bone loss; stimulation of
hepatic production of sex hormone-binding
globulin (SHBG), thyroid-binding globu-
lin, plasminogen, and blood clotting factors
VII–X; inhibition of antithrombin III and
low-density lipoprotein (LDL) formation;
and many others. Phytoestrogens differ in
the combination of these actions they
express and can be characterized as anticar-
cinogens, antioxidants, antiviral agents, and
so forth. For example, genistein (GEN) can
be characterized as a protein tyrosine kinase
inhibitor, in contrast to its inactive chemi-
cal analogs daidzein (DAI) and chrysin. The
latter phytoestrogens are equal or more
potent inhibitors of steroid-metabolizing
enzymes such as aromatase and 17-hydroxy-
steroid dehydrogenase (8,9). 
The two major classes of phytoestrogens
are lignans and isoflavonoids (Table 1).
Some structurally related flavonoids also
exhibit estrogenic properties. Lignans are
minor components of cell walls and ﬁbers of
seeds, fruits, berries, vegetables, grains, and
nuts. The isoflavonoids are prominent in
legumes, especially soybeans, but detectable
levels occur in whole-grain products, pota-
toes, fruits, vegetables, and alcoholic bever-
ages (9,10), and in cows’ milk, meat, and
even fish grown with soy-containing food
(11). The isoﬂavonoids are divided into three
major classes: isoflavones, isoflavans, and
coumestans (Table 1). The best-known
isoflavones are GEN and DAI, which are
formed from the plant precursors for-
mononetin (FRM) and biochanin A, respec-
tively. The most signiﬁcant isoﬂavan is equol
(EQL) (Table 2), a metabolite of DAI.
Coumestrol (COM) is the best-known
coumestan and the isoflavonoid with the
highest estrogenic potency (12). The mycoe-
strogens are estrogenic fungal products that
are not intrinsic components of plants but
are found in pasture grasses and legumes
infected by the fungal genus Fusarium. 
Phytoestrogen Actions
Estrogen Receptor Afﬁnity 
and Activation
Estrogen receptor binding is the best-
documented action of phytoestrogens.
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Numerous studies have shown that the
isoﬂavonoids and lignans, as well as the fun-
gal estrogens, compete effectively with estra-
diol (E2) for binding to ER-rich cells or
cytosol (Table 2). Interpretation of these
data is complicated by the recent discovery
that ERs are divided into two distinct sub-
types: the originally sequenced ER, ERα,
and a newly discovered variant, ERβ, with
95% homology in the DNA-binding region
but only 55% homology in the ligand-
binding domain (12). Binding studies using
the purified receptor proteins show that the
isoflavonoids COM and GEN are very
active competitors for both receptor sub-
types, but bind more avidly to the beta than
to the alpha subtype (Table 2). COM has a
2-fold higher afﬁnity for ERβ than for ERα,
whereas GEN has a 30-fold higher affinity
for ERβ (12). A recent study using human
hepatoma cells has now shown that DAI also
binds to ERβ with a higher affinity than
ERα (13). This differential affinity is likely
to be of functional significance, as the two
receptor subtypes have different distribu-
tions across estrogen-responsive tissues
(12,14–16) and during development (17).
Moreover, as none of the common screening
tests for estrogens such as ligand competi-
tion assays using rodent uterine cytosol or
cell proliferation assays using breast cancer
cells [e.g., E-SCREEN (18)] or recombinant
cells containing ERα and an estrogen-
responsive reporter gene [e.g., recombinant
yeast cell bioassay (18)] include significant
concentrations of ERβ (18,19), phyto-
estrogen potency may be underestimated. 
Recombinant assays provide evidence
that phytoestrogens not only bind to ERs
but also initiate gene transcription. These
assays are based on recombinant yeast cells
containing an ER and one or more estrogen
response elements (EREs) linked to genes
for reporter proteins like β-galactosidase
(GAL) (20), chloramphenicol acetyltrans-
ferase (CAT) (20), or human placental alka-
line phosphatase (21). These assays have
demonstrated that isoflavones, coumestans,
and mycoestrogens all induce ERE-linked
reporter proteins (Table 2). Most of these
assays are based on ERα, but a recent study
has shown that GEN activates reporter gene
expression through both ERα and ERβ
(21). However, in spite of GEN’s higher
affinity for ERβ, it may be a more effective
inducer of ERα-mediated actions. Although
GEN was slightly more potent via ERβ-
linked reporters, it was less efficacious, dis-
playing only partial agonism via ERβ but
full agonism via ERα (21). Phytoestrogens
can also alter the expression of receptors for
hormones other than estrogen, including
receptors for progesterone (PR), oxytocin
(OTR), and testosterone (AR). In cell cul-
ture assays GEN induces PR expression at
doses 1,000-fold lower than the concentra-
tion required to act as a tyrosine kinase
inhibitor (22). GEN also acts as an anti-
androgen in a dose-dependent fashion in a
breast cancer cell line (23).
Perhaps the most compelling data come
from in vivo studies using oral doses of phy-
toestrogens. Oral doses of DAI too low to be
uterotropic significantly reduced mRNA
expression of AR and ER in the rat uterus
while upregulating the expression of comple-
ment 3, a gene known to be sensitive to
estrogen, in a dose-dependent fashion (24).
A 0.01% COM diet also failed to signifi-
cantly alter uterine weight in female rats but
significantly decreased OTR expression in
the hypothalamus (25). These studies suggest
that phytoestrogen can have a significant
impact at the molecular level at doses too low
to produce gross physiologic changes. 
Postreceptor Activation 
Some isoﬂavones and ﬂavones inhibit protein
tyrosine kinases (26,27), which play impor-
tant roles in cell signal transduction and the
regulation of the cell cycle (Table 3). GEN is
the most potent inhibitor. GEN can also
inhibit DNA topoisomerases I and II,
enzymes essential for DNA replication
(28,29), and is the most powerful antioxidant
of the phytoestrogens. It also has the ability
to increase the activities of antioxidant
enzymes as well as directly inhibit hydrogen
peroxide production. 
Hormone Synthesis
Phytoestrogens have the potential to affect
steroid biosynthesis and metabolism through
a number of pathways (Table 3). A variety of
in vitro assays have now shown that
isoﬂavones and lignans are inhibitors of aro-
matase (30,31) and 5α-reductase (32). A
number of phytoestrogens also inhibit 17β-
hydroxysteroid dehydrogenase Type I (33). 
However, these effects may not be as
pronounced in vivo. Male rats fed a diet
containing mulitple phytoestrogens (224
µg/g DAI, 319 µg/g GEN, and 39.5 µg/g
glycitin) for 70 days showed no change in
hypothalamic aromatase activity, even
though isoﬂavone levels were 8 times higher
in the brains of these animals than in the
controls (34). Similarly, male rats fed a diet
containing 200 µg/g phytoestrogens for 29
days also showed no significant changes in
aromatase activity in either the amygdala or
the preoptic area. However, significant
changes were seen in both areas in the activ-
ity of 5α-reductase (35). The difference
between the in vitro and in vivo data may
stem from the significant role metabolism
and the actions of binding proteins and sec-
ond messenger systems play in the activity of
phytoestrogens. 
Cell Proliferation
Cell growth assays provide evidence that
phytoestrogens can either enhance or suppress
proliferation in estrogen-responsive cells,
depending on their concentration and relative
potency (RP) (Tables 4 and 5). COM, GEN,
and α-zearalenol (α-ZEL) exhibit minimal
antagonism of E2 in cancer cell or recombinant
yeast cell assays and sometimes even augment
its action (Table 5). The weaker phytoestro-
gens, such as biochanin A and enterolactone
(ENL), are antagonistic at higher levels,
whereas ﬂavonoids like phloretin (PHL), nari-
genin, kaempferol (KMP), apigenin (APG),
Table 1. Major types and families of phytoestrogens.
Flavonoids
Isoﬂavones
DAI
Dihydrodaidzein
Formononetin
GEN
Biochanin A
Ononin
Prunetin
Isoﬂavanones
O-Desmethylangolensin
Isoﬂavans
Equol
Equol diacetate
Coumestans
Coumestrol
Coumestrol diacetate
4-Methoxycoumestrol
Hydroxychalcones
Phloretin
Isoliquiritigenin
4,4´-Dihydroxychalcone
Flavones
Flavone
Apigenin
7-Hydroxyﬂavone
4´,5-Dihydroxyﬂavone
Flavone acetic acid
4´,6-Dihydroxyﬂavone
7,8-Dihydroxyﬂavone
Chrysin
Tangeretin
Flavonols
Kaemperide
Kaemperfol
Quercetin
Flavanones
4´,7-Dihydroxyﬂavanone 
Naringenin
Lignans
Enterolactone
Enterodiol
Matairesinol
Secoisolariciresinol
Resorcylic acid lactones
Mycoestrogens
Zearalenone
α-Zearalenol
α-Zearalanol (zearanol)
β-Zearalenol
β-Zearalanol
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and β-ZEL have been reported to display
triphasic activity, inhibiting estradiol at low
and high concentrations and augmenting
estrogen action at intermediate levels (18).
Hormone Transport
Interactions with binding proteins can have
important effects on the RP of estrogens.
Although serum albumins do not affect the
bioavailability and activity of serum hor-
mones, SHBG and α-fetoprotein differen-
tially reduce sex-steroid availability, resulting
in relatively greater bioavailability of estro-
gens that bind only weakly to these glyco-
proteins (36). Reports of phytoestrogen
interactions with binding globulins are
somewhat contradictory. An early study
using dilute human serum reported phyto-
estrogen relative binding affinities of
14–27% (37), but affinities estimated in
more recent studies using partially purifed
SHBG range from 0.01 to 0.1% (38,39)
(Table 6). The low affinity of isoflavonoids
would be expected to result in enhanced
bioavailability in the presence of SHBG, and
in fact the effective free fraction of COM
and GEN in human serum is 45–50%,
whereas only 4% of E2 is free (40). Addition
of human serum to whole-cell binding assays
raises the relative binding affinity of
isoflavonoids 10-fold (40), but normal
serum concentrations of SHBG (0.002
mg/mL) reduce the activity of COM and
GEN in the yeast estrogen screen assay by
only 5–10%, which is similar to the reduc-
tion of E2 activity (5%) (41). However,
pregnancy concentrations of human α-feto-
protein (40–160 mg/mL) reduce the activity
of E2, COM, and GEN by 50% (41). 
Sequestering steroids is not the only
action of binding globulins; binding globu-
lins also contribute to hormone uptake by
target cells (42,43–45). Cellular uptake of
albumin- and SHBG-bound estrogens pre-
cedes their interaction with nuclear receptors
and may directly affect the delivery of hor-
monal signals. Whereas free estrogens and
the albumin-bound fraction are internalized
into the cytoplasm, SHBG–estrogen com-
plexes bind to membrane receptors, initiating
nongenomic influences on cell metabolism
through second messenger systems and prim-
ing effects on nuclear super-receptor com-
plexes. ATP-binding cassette carriers within
cell membranes also may expel estrogens out
of cells, preventing their entry into the brain
and other tissues. GEN binds to both the
multidrug resistance protein (46) and P-glyco-
protein (47), but only relatively high concen-
trations (200–400 µM) have been tested.
These transport glycoproteins have low total
capacity; ligands compete with one other for
the binding sites, with the result dependent
on the relative concentrations of binding
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proteins and endogenous and exogenous
estrogens (9,48,49). These interactions may
play a role in the selectivity of the blood–
brain barrier and other tissue–blood barriers
and in absorption from the intestine.
Although phytoestrogen influences on these
processes are not well understood, their afﬁn-
ity for all these binding proteins and rela-
tively high concentrations in plasma provide
opportunities for significant effects on these
mechanisms of hormone uptake.
In addition to binding competition,
phytoestrogens might also inﬂuence estrogen
availability by raising SHBG synthesis (9).
The clinical evidence for this effect is mixed,
with some studies demonstrating an increase
in SHBG levels in postmenopausal women
on a soy-based diet (50) and other studies
showing no change in SHBG levels (51–53)
or even a decrease (54) in SHBG on soy-
based diets. 
Phytoestrogen Potencies 
and Active Concentrations
Estimates of estrogenic potency vary across
assays. Because recombinant cells often contain
multiple copies of EREs, resulting in E2 sensi-
tivities as low as 0.1–7 pM, these assays can
underestimate the in vivo concentrations
required for estrogen action (55). Purified
receptor preparations also provide unrealistic
estimates of binding affinity caused by the
absence of binding proteins. Cytosol and
whole-cell assays provide more accurate esti-
mates of potency, with effective concentrations
in the picomolar to nanomolar range for E2. 
Generally, lower concentrations are
required for ER-mediated events and for cell
proliferation than for other types of
responses. The range of estrogen concentra-
tions required for stimulation of cell prolifer-
ation varies across assays, but in general,
concentrations of 1–100 nM stimulate cell
growth by isoﬂavonoids (Table 4). Relatively
high concentrations, ranging from 5 to 100
µM, are generally required for suppression of
proliferation (Table 5), and biphasic patterns
are frequently seen, with proliferative actions
occurring at nanomolar concentrations and
inhibition of proliferation occurring at
micromolar concentrations. There is
evidence that lower concentrations of GEN
are required to suppress environmental estro-
gen-stimulated cell proliferation if other phy-
toestrogens are also present. However, the
concentrations required for these additive
effects (25 µM) are still quite high, so it is
unclear if the action would occur in vivo
(56). Similarly, high micromolar levels are
required for estrogen antagonism of cell pro-
liferation, with minimal action by the most
potent phytoestrogens. 
Inhibition of tyrosine receptor kinases and
other targets of phosphorylation occur at
micromolar concentrations (Table 3).
Micromolar concentrations are required for
lignan and isoflavone binding to SHBG
(5–50 µM) (38) and α-fetoprotein (Kd:
0.5–5 µM) (57,58). Concentrations required
for inhibition of most steroid metabolizing
enzymes are generally in the micromolar
range, with the exception 17β-hydroxysteroid
dehydrogenase type I, which is inhibited by
isoﬂavonoids at concentrations ranging from
120 nM to 1 µM (33,59). 
Phytoestrogen Exposure
Dietary Sources
The highest concentrations (1–3 µmol/g) of
lignans are found in flaxseed (linseed) prod-
ucts (60,61), which are consumed by some
Europeans. Good sources of lignans in the
United States and Europe are pumpkin seed
(20 mg/100 g), sunflower seed, cranberry,
black tea, coffee, garlic, broccoli, brans, and
peanuts (62). Green tea is a rich source of lig-
nans and a popular beverage in many Asian
countries (63). 
Phytoestrogenic isoflavonoids are less
prevalent than lignans. The highest concen-
trations are found in legumes, especially in
soybeans and soybean-based products, which
can contain as much as 0.2–1.6 mg of
isoflavones per gram dry weight (64). The
isoﬂavone contents of the basic food types are
summarized in Table 7.
Plasma Concentrations
Humans. Phytoestrogen exposures vary sub-
stantially across human populations and indi-
viduals (Table 8). Differences across
populations are related to dietary variation
(9,65), whereas within-population variation
smay reflect individual differences in the
intestinal microflora, local differences in the
phytoestrogen content of foods, and dietary
effects on phytoestrogen absorption and
metabolism (11,66,67). Asian diets are partic-
ularly high in soy, resulting in isoﬂavone con-
sumption as high as 1 mg/kg body weight
(bw)/day, whereas vegetarian diets are high in
whole grains, vegetables, and legumes, result-
ing in higher consumption of lignans. These
dietary exposures produce plasma isoflavone
concentrations as high as 1 µM in Japanese
men and women consuming a traditional
diet. In Europe and North America, plasma
concentrations are generally less than 0.07
µM for omnivores, whereas vegetarians may
have levels as high as 0.4 µM isoﬂavones and
0.8 µM lignans. A recent study of Japanese
infants indicates that isoﬂavonoids gain access
to fetal tissues, resulting in concentrations in
cord blood and amniotic ﬂuid (0.2–0.3 µM)
similar to maternal plasma concentrations
(0.2 µM) (68). 
Feeding trials provide more detailed
data on phytoestrogen bioavailability in
adults (Tables 9,10). Single soy meals pro-
viding isoflavone doses of 0.06–1.2 mg/kg
(4–71 mg) produce peak plasma concentra-
tions of 0.06–2.2 µM. Peak plasma concen-
trations of GEN and DAI are reached
within 4–8 hr, with an absorption half-life
of 1–3 hr. The excretion half-life ranges
from 3 to 8 hr. DAI, with estimates ranging
from 16–66%,  appears to be more bio-
available than GEN (5–37%).
The highest human dietary exposures
occur in infants fed a soy-based formula
Table 3. Enzymes inhibited by phytoestrogens in vitro.
ED50
End point Ref DAI FRM GEN BIA EQL COM APG QUC ENL ZLN 
Ovarian and placental aromatase (88–90) Inactive Inactive 3.5 µM 2.2 µM 150–850 µM Inactive 1.2 µM 12 µM 14 µM
Preadipocyte aromatase (30,175) 113 µM 17. µM 74 µM
17β-Hydroxysteroid dehydrogenase (33) 1.2 µM 0.1 µM Inactive
5α-Reductase (32) 35 µM
In vitro angiogenesis (176) 100–200 µM
EGF TKE (177) 2.6 µM
EGF TKE (intact cells) (178) Inactive
Protein kinase C (177) > 111 µM
Phosphatidylinositol 3-kinase (179) Inactive 12 µM 10 µM
Hydrogen peroxide production (180) 150 µM 25 µM Inactive
Superoxide anion production (180) 5 µM 1–2.5 µM Inactive
LDL oxidation (181) 56 µM 13 µM 44 µM
Microsomal lipid peroxidation (182) Inactive Inactive 95 µM 53 µM 12 µM 5 µM
TKE, tyrosine kinase-enzyme.
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Table 4. Estrogenic potency: in vitro range of concentrations for estrogenic actions.
End point Ref E2 DAI FRM GEN BIA DMA EQL COM APG KMP QUC IPR ENL ZLN α-ZEL α-ZAL β-ZEL β-ZAL
ER binding
ERα protein (12) 0.2 nM 4.2 nM 0.2 nM 1.3 nM
ERβ protein (12)  0.1 nM 0.4 nM 0.1 nM 0.9 nM
Uterine cytosol  (165,167) 0.002 nM 1 µM 49 mM 100 nM > 10 µM 2 µM 250 nM 20 nM 714 nM 4 nM 5.9 nM 232 nM 294 nM
Mammary cytosol (111) 200 nM
MCF7 cells  (104,149)  0.2 nM 61 nM 200 nM 200 nM 1.6 µM 20 µM Inactive 
hER transfect COS7 cells (169) 1 nM 60 µM > 100 µM
hER transfected yeast  (18) 1 nM 2 µM 6 µM 10 nM 44 µM 22 µM 6 µM 30 µM
Induced proteins
pS2 in MCF7  (104) 0.2 nM < 1 µM 200 nM 200 nM 1µM 10 µM ≥ 1 µM
Exoprotein in MCF7 (20) 0.03 nM 2.5 µM 3 mM 300 nM 2.5 mM 100 nM 0.6–1 nM
Cyclin D1 in MCF7  (183) 1 nM 500 nM  500 nM 
Prolactin (112) 0.01 nM 10 mM 1 µM 100 nM 10 µM 10 µM
Luciferase in MVLN  (183) 1 nM 100 nM 10 nM 
GAL in hER yeast  (41) 0.2 nM 100 nM 20 nM
GAL in hER yeast (165) 0.001–1nM 1 nM–10 µM 0.1–1,000 nM 0.1 nM–1 µm
CAT in hER LeC9  (20) 0.2–30 nM 10–50 µM 1–50 µM 600–4,000 nM 50 nM
CAT in hER FLG29.1 (169) 10 nM > 1 µM >1 µM
Intracell signals
Cdk2 in MCF7 (184) 1  nM 1  µM 1 nM
pRb105 in MCF7 (184) 1 nM 500 nM 500 nm
Cell proliferation
(Active range)
MCF7 cells (172) 0.001 nM 0.01–100 µM 10 nM–0 µM 0.1–10 µM 10 nM–10 µM
MCF7 cells (104,142)  — < 1 µM 1 nM–10 µM 0.01–10 µM 10 nM–1 µM 1–10 µM Inactive < 1 µM 10–100 nM
MCF7 cells (185) 0.5–1 nM 0.5–10 µM
T47D cells (104) 0.01–1 nM 10 nM–6 µM 
T47D cells (33) — 100 nM–1 µM 0.1–1 µM 0.01 nM–1 µM Inactive 300 nM Inactive 0.01 nM–1 µM
Abbreviations: Cdk2: cylcin-dependent kinase 2; pRb105: retinoblastoma susceptibility gene product.
Table 5. In vitro concentrations for estrogen antagonism, augmentation, and antiproliferative actions.
Cell type End point Ref DAI GEN BIA DMA EQL COM PHL KMP QUC NAR ENL ZLN α-ZEL
Brain capillary BBCE Antiproliferative ED50 (176) 90 µM 5 µM 50 µM 30 µM
Breast MCF7 Antiproliferative (104,172)  Inactive 18–111 µM 50–100 µM > 20 µM 50–100 µM 20 µM .01–20 µM 50 µM
(108,185)
Inhibit 5 nM E2 (56) 25 mM
Inhibit 1 nM E2 (185) 1 mM
Inhibit 10 µM DDT (56) 25 µM
Augment 0.3 µM DDT (184)1  µ M 1 nM
Breast T47D Antiproliferative (104) 10–20 µM 
Inhibit 0.3 nM E2 30–300 µM
Augment 0.1 pM E1 (33) 1–100 nM 1–100 nM
Breast MDA48 Antiproliferative (108) 18–111 µM
Prostate LNCAP Antiproliferative (108) 18–111 µM
Prostate DV145 Antiproliferative (108) 18–111 µM
hER transfect yeast Inhibit 1 nM E2 (18) Inactive 0.1–10 µM Inactive 0.01–10 µM 1–100 pM Inactive
Inhibit 1 µM 4-0H-PCB 0.1–10 µM > 1 µM > 10 nM
Augment 250 nM COM 1 µM
Abbreviations: BBCE, bovine brain capillary endothelial cells; 4-OH-PCB, 4-hydroxy-polychlorinated biphenyl.
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(SBF). SBF contains high concentrations of
isoflavones (100–175 µM), significantly
more than breast milk before (18–56 nM) or
after (10–70 nM) soy consumption (69) or
in bovine based-milk formula (70,71). An
infant fed only SBF consumes approximately
6–11 mg/kg/day isoﬂavone, which is consid-
erably more than the average for adults, even
on a soy-rich Asian diet (0.3–1.2 mg/kg/day)
(72,73). These high intakes result in
markedly higher plasma concentrations
(2.4–6.5 µM) in infants fed a soy milk diet
than in infants fed either cows’ milk formula
(0.03 µM) or breast milk (0.02 µM) (71,74),
plasma levels that are 10-fold higher than the
average levels reported for Japanese women
and equal to those seen at peak plasma levels
following soy challenges in adults.
Animal models. Species differences in
metabolism may influence bioactive doses.
For example, relatively high oral doses are
required to produce micromolar concentra-
tions in plasma in sheep, whereas similar
peak concentrations can be achieved in cat-
tle and pigs with lower doses (Table 11).
However, few studies have examined the
pharmacokinetics of isoflavones in rodent
models of estrogen action. Estimates of
bioavailability of GEN in rats and mice
(10–20%) are similar to values reported for
humans (Tables 10,11); however, the doses
tested in rodents are substantially higher
than the doses tested in humans and use free
GEN rather than the GEN glycosides pre-
sent in the soy protein generally used in
human trials. Peak plasma levels are
achieved in rats within 2 hr and in mice
within 3–30 min after oral dosage (Table
11). Single or repeated oral GEN doses of
20–45 mg/kg produce peak plasma concen-
trations of 2–11 µM in rats. Single oral
doses of 50–200 mg/kg GEN produce peak
free plasma concentrations of 1–4 µM in
mice. These doses are considerably higher
than those reported to produce micromolar
plasma levels in humans, but data on plasma
concentrations resulting from lower dietary
doses in rodents will be required to deter-
mine whether these dose responses represent
species differences.
Tissue Concentrations
Only a few studies have examined phyto-
estrogen concentrations in tissues and bod-
ily fluids other than plasma and urine
(Table 12). Single-dose treatment of female
mice with 40 mg/kg/day subcutaneous (sc)
FRM produced peak plasma concentrations
of 9 µM in 2 hr and peak mammary tissue
concentrations of 7 nmol/g in 4 hr, with
mean half-lives of elimination of 2 and 2.5
hr, respectively (75). In rats, plasma levels
of EQL increased from 91 to 450 nM 1 hr
following a single sc injection of 4 mg/kg
EQL, and the corresponding uterine con-
centrations were 0.4 and 4 nmol/g (76).
Chronic oral doses of 8–40 mg/kg GEN
resulted in reproductive tissue concentra-
tions of 0.3–1.4 nmol/g (77). On a parts
per million basis, total isoflavone levels in
rodent plasma and mammary gland appear
to be quite similar. However, the high pro-
portion of GEN aglycone in reproductive
tissues compared to serum suggests that
some accumulation occurs (77).
A very small sampling of human breast
milk (HBM) suggests that isoflavone
concentrations are lower in breast milk than
in plasma (69,78) (Table 12). On the other
hand, a large sample of prostatic fluid
concentrations indicates that isoflavone and
lignan concentrations are higher on average
than mean plasma levels (79,80) (Table 12).
Plasma and prostatic ﬂuid concentrations in
individual men were well correlated for DAI
(rs = 0.7) but not for enterolactone (rs =
0.2–0.4) (80), suggesting that isoﬂavones are
concentrated in the prostate. 
The most illustrative study to date used
an oral dose of [14C]GEN (4 mg/kg) in male
and female rats (81). The highest concentra-
tion of radioactivity was found in the gut;
significant levels of radioactivity were also
found in a variety of other organs, particu-
larly the liver and reproductive organs, but
also the brain, heart, lungs, and kidneys.
Interestingly, retention in the liver was sexu-
ally dimorphic, with females showing nearly
2.5 times the radioactivity as males 2 and
7 hr after the initial dose was given. 
Exposure and Bioactivity
The data reviewed above indicate that total
plasma levels of isoﬂavonoids and lignans in
humans range from 10 to 400 nM, of which
only about 10% (1–25 nM) is unconjugated
(Table 8). Plasma concentrations as high as 2
µM total isoﬂavonoids may be achieved for a
few hours after food consumption. Limited
data for tissue concentrations indicate no
more than nanomolar levels, even in tissues
like the prostate where isoﬂavonoids may be
concentrated relative to plasma. Therefore,
overall it appears that average concentrations
may be too low to induce most of the
reported in vitro actions other than those
mediated by ERs (Table 3). Moreover, cur-
rent data suggest that agonism and cell pro-
liferation are more likely than antagonism
and suppression of cell proliferation.
However, the latter predictions may be
biased by the ERα-based systems from which
they were drawn, and a different picture may
emerge from assays based on ERβ. 
In Vivo Actions
A variety of in vivo actions of phytoestrogens
have been reported in animal experiments
Table 6. Phytoestrogen afﬁnities for binding proteins.
End point Ref E2 DAI FRM GEN EQL COM KMP QUC NAR ENL END ZLN α-ZEL
Human serum RBA, %E2 (37) 100 24 27 14 5 21
SHBG afﬁnity RBA, %E2 (38) 0 0.03 0.05 0.1 Inactive
Human serum RBA, %E2 (39) 100 0 < 0.01 0
Rat α-fetoprotein Kd, %E2 (58) 100 0.1 0.1 0.1 1 1 1
Rat α-fetoprotein RBA, %E2 (39) 100 < 0.1 0 < 0.1
SHBG comp ED50 (186) 0.0031 µM 4.5 µM 1.9 µM
SHBG comp ED50 (38) 0.02 nM > 100 µM 30 µM 20 µM 10 µM > 100 µM
Rat α-fetoprotein Kd (58) 5 nM 5 µM 5 µM 0.5 µM 0.5 µM 0.5 µM
Rat α-fetoprotein Kd (57)  3 nM 6.7 µM 17 µM 22 µM
P-glycoprotein minimum active (47) 200 µM
Multidrug resistance protein (46) 400 µM
minimum active
Abbreviations: END, enterodiol; RBA, relative binding afﬁnity; SHBG comp ED50, SHBG competitive binding afﬁnity, 50% estrogen displacement.
Table 7. Isoﬂavone and lignan content of human foods.
Food GEN DAI Lignans
mg/100 g
Fruit 60–200
Vegetables 1–3 1–3 100–400
Cereals 100–700
Flaxseed 68,000
Soy products 20–1,100 20–900 900
Fava beans 100
Indian bread root  200
leaves
Kudzu root 95
Other nonsoy  0–80 0–10
legumes
Data from Aldercreutz and Mazur (9), Thompson et al. (61), Reinli
and Block (187), and Kaufman et al. (188).
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and human clinical studies. Although the
majority of these actions are in the reproduc-
tive tract, there is evidence for effects on
functions of the cardiovascular, skeletal, and
central nervous systems. 
Proliferation of Uterine and 
Vaginal Epithelium
Proliferation of the female reproductive tract
is a classic test of estrogenicity that has been
demonstrated for a number of phytoestrogens
in a variety of animal species (Table 13).
More variable results have been achieved
using soy treatments. A soy-based diet pro-
viding 7 mg/kg/day GEN and 3 mg/kg/day
DAI to ovariectomized rhesus macaques did
not induce uterine growth or maturation of
the vaginal epithelium, although they pro-
duced significant changes in cardiovascular
risk factors (see below) (82). A similar diet
also failed to alter uterine growth or vaginal
cytology in ovariectomized rats (83). 
More variable results have been obtained
with postmenopausal women. Soy protein
supplements that provided postmenopausal
women with 0.7 mg/kg/day GEN and 2.1
mg/kg/day DAI over a 4-week period did not
significantly alter the vaginal maturation
index, although there was a trend for an
increase in superﬁcial cells (84). On the other
hand, increases in the maturation index
were observed in an Australian study during
6-week supplementation with a soy flour
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Table 8. Mean plasma isoﬂavonoid and lignan concentrations in human populations consuming typical diets.
DAI GEN DMA EQL Total ENL END MAT Total
Locale Diet Sex/age (nM) (nM) (nM) (nM) (nM) (nM) (nM) (nM) (nM) n Ref
Total
Spain OM M 1.3 0.4 3.9 0.4 4.3 50 (80)
United Kingdom OM M 8.2 0.6 3.9 3.9 36 (80)
Finland OM M 6.2 6.3 < 0.1 0.3 12.9 14 (189)
Canada OM M 3.4 8.2 11.6 13.9 1.9 15.0 10 (190)
Hong Kong OM M 31.3 3.8 6.2 1.7 7.9 53 (80)
Japan OM M 107.0 276.0 3.3 5.5 391.8 14 (189)
Finland OM F-PRE 4.2 4.9 0.1 0.8 10.0 28.5 1.4 0.0 314.9 14 (191)
Finland VG F-PRE 18.5 17.1 0.8 0.7 37.1 89.1 5.4 0.1 94.6 14 (191)
Finland LV F-PRE 41.5 29.7 1.8 1.0 74.0 752.7 65.6 1.9 820.2 3 (191)
Finland OM M 0.6 0.5 < 0.1 0.1 1.3 14 (189)
Japan OM F-PG 232 (68)
Japan OM F-PRE 72.5 206.1 (192)
Japan OM NCB 299 (68)
NAF 223
United States HBM Infant 3600
CMF 34
SBF 17 (71,73)
Free + sulfate
Japan OM M 12.8 7.8 1.8 0.6 23.0 14 (189)
Finland OM F-PRE 0.7 0.7 0.0 0.0 1.4 4.9 0.2 0.0 290.1 14 (191)
Finland VG F-PRE 3.2 1.3 0.1 0.2 4.8 16.8 0.7 0.0 302.5 14 (191)
Finland LV F-PRE 6.5 1.1 0.6 0.3 8.4 203.6 17.2 0.8 221.6 3 (191)
Abbreviations: CMF, cows’ milk formula; END, enterodiol; F, female; LV, lacto vegetarian; M, male; NAF, neonatal amniotic ﬂuid; NCB, neonatal cord blood; OM, omnivorous; PG, pregnant; VG, vegetarian.
Table 9. Human plasma and urinary isoﬂavone concentrations following a single dietary dose.
Daidzein Genistein
Dose Dose Peak plasma  Urine Dose Dose  Peak plasma  Urine
mg/day (mg/kg/day) (nM) (µmol/day) Ref (mg/day) (mg/kg/day) (nM) (µmol/day) n Ref
0 0 3.8 (193) 0 0 1.2 12 (193)
0 0 3.8 (194) 0 0 1.1 12 (194)
00 3 ( 190)0 0 8 1 0 ( 190)
0 0 0.3 (66) 0 0 0.2 17 (66)
0 0 0.2 (53) 0 0 1.8 21 (53)
3.9 0.06 60 (78) 4.4 0.07 100 2 (78)
7.9 0.1 500 (78) 8.9 0.14 350 2 (78)
15.7 0.3 1,400 (78) 17.8 0.3 1,300 2 (78)
21 0.4 1,400 51.8 (195) 19.3 0.3 740 3.6 12 (196)
21 0.4 3.6 (66) 30 0.5 1,300 14.4 7 (195)
24.7 0.4 790 19.0 (196) 34 0.6 1,400 19.2 7 (195)
26 0.4 1,500 59.0 (195) 37 0.6 11.5 40 (53)
27 0.4 22.2 (53) 38 0.6 8.4 12 (194)
27 0.4 424 (197) 36.2 0.6 1,070 14.3 12 (196)
0.4 498 (155) 44 0.7 1.7 17 (66)
32 0.5 14.7 (194) 55.7 0.9 2,150 20 12 (196)
34 0.6 3.9 (66) 1.0 907 (155)
35.6 0.6 498 (190) 73 1.2 1.7 17 (66)
45.9 0.6 1,220 41.9 (196) 80 1.3 907 10 (190)
70.7 1.2 2,224 56.4 (196)
80 1.3 14.7 (193)
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isoflavone doses (e.g., about 1–2 mg/kg/
day) (84). This study did not include a con-
trol group, however, so the results are diffi-
cult to separate from the normal waning of
menopausal symptoms over time. It may be
that the actual dietary content was higher,
as another Australian study that provided
the same supplement reported much higher
urinary excretion (45 µmol/day) of DAI
(86) than has been reported in other feeding
studies (Table 8); however, the latter study
did not observe any changes in vaginal cytol-
ogy. Two more recent studies did not observe
changes in vaginal cytology during soy
supplementation (50,87).
Ovarian Cyclicity
Phytoestrogens could inﬂuence ovarian cycles
through several pathways. Phytoestrogen inter-
action with ERs in ovarian granulosa cells
might augment or inhibit follicular develop-
ment, especially in light of the high afﬁnity of
isoﬂavones for ERβ. ERβ is abundant in gran-
ulosa cells, although the high intraovarian
concentrations of E2 may limit the potential
for such effects. Phytoestrogen inhibition of
ovarian aromatase (88–90) could reduce the
availability of endogenous estrogen and limit
follicular development. However, the very
high concentrations required for inhibition
by isoﬂavones (Table 3) make it unlikely that
they would significantly influence estrogen
production in the ovary. A more likely route
for isoﬂavone inﬂuences on E2 bioavailability
would be via inhibition of 17-hydroxysteroid
dehydrogenase type I, an effect that occurs at
concentrations of 0.1–1 µM (33,59). In
addition, phytoestrogens could augment or
inhibit estrogen negative feedback by
binding to ERs in the anterior pituitary or
hypothalamus and indirectly alter ovarian
steroidogenesis (see below). 
Natural dietary exposures to phytoestro-
gens have been associated with cystic ovaries,
irregular estrus, and anestrus in cattle (91), and
reduced breeding success in California quail
(92). Compromised follicular development
(91) and reductions in luteal phase plasma
progesterone and E2, as well as shortened luteal
phases, have been reported in cycling ewes
whereas increases in estradiol and cortisol have
been reported in pregnant ewes (93,94). Soy
isoflavone diets providing doses of 1
mg/kg/day were associated with infertility in
captive cheetahs (95).
Experimental studies of rats suggest that
effects on ovarian cycles depend on the hor-
monal milieu. For example, a 0.01% dietary
concentration of COM (a dose of 16 mg/kg
bw/day) hastened the onset of ovarian cycles
in immature females but suppressed ovarian
cycles when provided to cycling adult females
(96). Although the suppression of cycles is
reversed upon cessation of treatments, prepu-
bertal exposure may affect cyclicity later in
life. Rats treated prepubertally with 500
mg/kg/day sc GEN spent more time in the
estrous stage of vaginal cycles at 50 days of
age (97), and rats treated prepubertally with
16 mg/kg/day oral COM exhibited more
cycle irregularities at 100 days of age (96).
Several studies have examined the effects
of phytoestrogen supplementation on the
human menstrual cycle, with variable results
(52,53,98–101) (Table 14). Isoﬂavone doses
of 0.8–3 mg/kg/day produced significant
changes in menstrual cycles, but the direct and
type of effect varied considerably across
studies. An increased length of the menstrual
cycle was the most common outcome, but this
change was accompanied by elevations as well
as declines in serum E2 and testosterone. The
practice of sampling hormonal levels on only a
few days of the cycle becomes problematical
when cycle length is altered, as the days com-
pared no longer represent comparable stages
of the cycle. A recent study reported consis-
tent reductions in urinary estrogens but mini-
mal changes in plasma estrogens, suggesting
that urinary steroids may be more sensitive
indices of changes in steroid production than
plasma concentrations (100,102). Two studies
have reported declines in periovulatory
luteinizing hormone (LH) and follicle-
stimulating hormone (52,100), a response
with implications for fertility suggestive of
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Table 11. Isoﬂavone absorption and excretion in animals.
Isoﬂavone Species Dose (mg/kg/day) Plasma peak Time to peak (hr) Plasma half-life Bioavailability (%) Ref
GEN, sc Rat 500 24 hr: 4.2 µM  (110)
GEN, oral Rat 20 11 µM 2  8.8 hr 20 (202)
Soy genistin, oral Rat 20 4.9 µM 2  8.8 hr 18 (202)
Soy GEN, oral Rat 20 9.5 µM 2  15 (203)
GEN, oral Rat 45 2.2 µM 2  (112)
GEN, oral Rat ~40 6–8 µM 3–4 hr (77)
Soy daidzein, oral Rat 21 5 µM 2  19 (203)
EQL, sc Rat 5  1 hr: 0.4 µM (76)
GEN, iv Mouse 52 237 µM 0.6–1.3  (204)
GEN, oral Mouse 45 2.6 µM free 0.3  4.8 hr 20 (204)
GEN, oral Mouse 54–180 4.1 µM free 0.05  4.7 hr 21 (204)
Genistin, oral Mouse 50 1.5 µM free 0.5  8 hr > 0.4 µM 11 (204)
FRM, sc Mouse 40 9.2 µM  2.5  (205)
GEN, oral Rhesus macaque 7 55 nM (free + sulfate) (82)
DAI, oral Rhesus macaque 3 21 nM (free + sulfate) (82)
FRM, oral Sheep 84 0.1 µM; 7 µM equol  1  (205)
FRM, oral Cow (15 g) 0.4 µM; 7 µM equol  1  (205)
FRM, oral Pig (0.9 g) 3.7 µM; 0.9 µM equol 1  (205)
Table 10. Estimates of isoﬂavone bioavailability in human subjects.a
Dose Peak Time  to  Absorption  Excretion
Isoﬂavone Source (mg/kg/day) plasma peak half-life half-life Bioavailability Ref
GEN Soy milk 0.3–0.8 5–11% (196)
GEN Soy milk 0.3–0.8 10–37% (198)
GEN Kinako 0.4 2.4 µM 6 hr 8.4 hr 20% (199)
GEN Tofu 0.6 13–16% (195)
GEN Soy ﬂour 1.0 4.1 µM 8.4 hr 4.7 hr 22% (200)
GEN Soy milk 1.7 2.2 → 1.4 3.8 hr 15% (201)
GEN Soy milk 1.8 2.7 → 2.0 6–8 hr 24% → 14% (99)
DAI Soy milk 0.4–1.2 16–32% (198)
DAI Soy milk 0.4–1.2 20–24% (196)
DAI Tofu 0.4 49% (195)
DAI Kinako 0.4 1.6 µM 6 hr 5.8 hr 56% (199)
DAI Soy ﬂour 0.8 3.1 µM 7.4 hr 5.7 hr 62% (200)
DAI Soy milk 1.5 1.6 → 1.4 4–6 hr 66% → 45% (99)
DAI Soy milk 1.7 1.5 → 2.5 2.9 hr 47% (201)
aEstimates of isoﬂavone bioavailability following ingestion of a soy-based product; dose gives the estimated intake in milligrams per
kilogram body weight per day.
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pituitary or hypothalamic actions of phyto-
estrogens. However, sample size and duration
of treatment limit the conclusions that can be
derived from these studies. The effects
observed after only a single cycle of treatment
may not be representative of the longer-term
consequences of phytoestrogen consumption.
Larger samples of women observed over
longer periods of treatment with controlled
doses are needed to establish the effects of soy
isoﬂavones on the menstrual cycle.
Proliferation of Breast Epithelium
Low rates of breast cancer in populations
with high phytoestrogen exposure suggest
phytoestrogens may inhibit epithelial cell
proliferation (9,65,103–106). On the other
hand, the biphasic effects on proliferation
observed in in vitro studies suggest that both
proliferative and antiproliferative effects
might be observed, depending on the dose.
Results from multiple in vivo studies across
species have been contradictory. A variety of
effects have been noted, ranging from
antiproliferation through enhanced prolifer-
ation, depending on the tumor cell type,
dose, timing of phytoestrogen exposure, and
the phytoestrogen given. In general the
isoflavones, and particularly GEN (likely
due at least partially to its tyrosine kinase-
inhibiting properties), produce the most sig-
niﬁcant results and are thus the most widely
explored.
Results seen in vitro have been difﬁcult to
reproduce in vivo. A recent study demon-
strated that GEN (20 µM) inhibits cell prolif-
eration in estrogen-independent human breast
cancer cells (MDA-MB-231) by as much as
50%. Mice with breast tumors produced by
inoculation with these same cells were then
placed on a GEN-rich diet (750 µg/g). No
signiﬁcant changes in tumor size or morphol-
ogy were seen, even when the treatment diet
was given before the initial innoculation with
the MDA-MB-231 cells (107).
Soy protein and GEN reduce tumor
multiplicity, but not incidence, in other ani-
mal models of breast cancer (Table 15). Soy
protein isolate-containing diets providing oral
doses of 2–8 mg/kg/day GEN and 1–3
mg/kg/day DAI reduced the number of
mammary tumors in 7,12-dimethylbenz[a]-
anthracene (DMBA)-treated rats (108). GEN
or DAI intraperitoneal (ip) injections that
provided doses ranging from 8 mg/kg/day at
35 days of age to 3 mg/kg/day at 215 days of
age resulted in an observable but nonsigniﬁ-
cant reduction in the number of mammary
tumors in N-methylnitrosourea (MNU)-
treated rats (109). The effect of DAI was
delayed compared with that of GEN. No sig-
nificant changes in protein tyrosine kinase-
mediated phosphorylation or topoisomerase
II activity were observed in the mammary
gland or mammary tumors, even with higher
isoflavone doses (40 mg/kg/day), suggesting
that the observed chemoprevention was
mediated via other mechanisms (109). Three-
day sc treatments with a much higher GEN
dose (500 mg/kg/day) during the neonatal
(110) or prepubertal period (97) resulted in
more marked reductions (50%) in tumor
number in DMBA-treated rats.
Stimulation of mammary tissue has been
seen in FRM-treated mice (111), GEN-
treated rats, (97,112), and in cattle grazing on
phytoestrogen-rich clover (113) (Table 15).
Five-day treatment with sc doses of 40
mg/kg/day FRM, resulting in peak plasma
and mammary levels of 9 µM and 4 nmol/g,
increased mammary gland proliferation in
ovariectomized mice (111). Oral doses of 36
mg/kg/day GEN maintained lobulo-alveolar
structure in ovariectomized rats without
affecting ducts; no effects were seen in imma-
ture rats (112). Transitory increases in
mammary gland weight also were produced
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Table 12. Tissue and ﬂuid concentrations of phytoestrogens.
Dose Peak plasma 
Species Isoﬂavone (mg/kg/daya) (nM) Fluid/tissue Concentration Ref
Mouse FRM, sc 40 9,200 Mammary 7 nmol/g (205)
Rat EQL, sc 5 400 Uterus 3 nmol/g (76)
Rat GEN, oral ~8 600–900 Mammary 0.3 nmol/g (77)
Uterus 0.8 nmol/g
Prostate 0.8 nmol/g
~40 6,000–8,000 Mammary 0.8 nmol/g
Uterus 1.4 nmol/g
Prostate 1.1 nmol/g
Human - United States GEN soy diet 0.07 100 Breast milk 30 nM  (78)
0.1 350 45 nM
0.3 1,300 70 nM
Human - United States DAI soy diet 0.07 60 Breast milk 15 nM (78)
0.1 500 32 nM
0.3 1,400 60 nM
Human - Lisbon DAI Norm. diet 5 Prostatic ﬂuid 18 nM (80)
Human - Hong Kong DAI Norm. diet 123 Prostatic ﬂuid 275 nM (80
Human - Hong Kong EQL Norm. diet 16 Prostatic ﬂuid 709 nM (80
Human - Australia EQL Unknown 158 (206)
Human - Australia DAI Unknown 1,147 (206)
Human - Australia GEN Unknown 544 (206)
Norm diet, normal diet.
aHuman mg/kg/day estimated based on a body weight of 60 kg. 
Table 13. Proliferative responses of uterine and vaginal epithelium to phytoestrogen treatments.
Dose (mg/kg/day)
End point Soy isoﬂavone FRM GEN BIA COM IPR α-ZAL Ref
Uterine growth
Immature mouse, sc 0.1–10 (165)
Immature mouse, oral  300–800 100–400 200–800 2–10 (174)
Immature/ovx rat, sc 0.5 200  (97,150)
Ovx rat, sc Inactive (150)
Immature rat, oral 16–160 (207)
Ovx rat, oral Inactive 58–590/1,800 calories 10–36 1–30 0.1–30 (83,112,142)
Ovx lact rat, oral  Inactive 2–17 (144)
Ovx heifers, oral 67 FRM + 40 BIA (113)
Vaginal cell maturation
Ovx rat, oral Inactive 58–590/1,800 calories (83)
Ovx longtail macaques 10 Inactive (82)
Human postmenopausal 2.8 Inactive (84)
Human postmenopausal 1–2 (85)
Human postmenopausal 1–2 Inactive (86)
BIA, biochanin A.
109S1.Part 1  2/21/01 4:52 PM  Page 13    (Black plate)Whitten and Patisaul
14 VOLUME 109 | SUPPLEMENT 1 | March 2001 • Environmental Health Perspectives
with three sc doses of 500 mg/kg/day GEN
in prepubertal and neonatal rats (97).
Moreover, soy isoﬂavones or oral GEN actu-
ally increased the growth of implanted MAC-
33 or MCF7 tumor cells in some recent
experiments in rats (114,115). However, soy
isoﬂavones did not increase mammary epithe-
lium proliferation in surgically post-
menopausal long-tailed macaques (116).
Early exposure to estrogen also may inﬂu-
ence susceptibility to mammary cancer by
altering the proliferation and differentiation of
epithelial structures that are sensitive to trans-
formation by carcinogens. Neonatal exposure
to E2 stimulates the mammary epithelium in
rodents, increasing terminal end bud prolifer-
ation and reducing the differentiation of ter-
minal end buds during the period from 4 to
16 weeks of age (117). This effect is hypothe-
sized to enhance susceptibility to carcinogene-
sis, as the terminal end bud is the site for
transformation in the rodent mammary gland
(118). Perinatal treatment with E2 or diethyl-
stilbestrol (DES) increases the incidence of
mammary tumors in mice carrying a mam-
mary tumor virus (119,120). Similar effects
have been observed with phytoestrogens.
Neonatal treatment with 10 mg/kg/day zear-
alenone (ZLN) increases the incidence of
spontaneous mammary tumors in Wistar rats
(121). Increased numbers and reduced differ-
entiation of terminal end buds have been
observed in mice after in utero exposure to
ZLN (117). 
Neonatal or prepubertal exposure to
GEN, however, appears to have the opposing
effect of enhancing terminal duct differentia-
tion in rats. Neonatal or prepubertal doses of
500 mg/kg/day GEN signiﬁcantly reduced the
number of terminal end buds and cell prolif-
eration indices at 50 days of age (97,110).
Transforming growth factor (TGF)-α and
epidermal growth factor (EGF) receptor were
upregulated in terminal duct structures imme-
diately after treatment, but the EGF signaling
pathway was downregulated by 50 days of age
(122). These data suggest that high-dose
GEN enhances epithelial differentiation.
However, in the absence of data on mam-
mary structure beyond 50 days of age, it is
difficult to evaluate whether the observed
changes represent permanent changes in
mammary organization or simply alterations
in the timing of developmental events.
Moreover, these high-dose treatments
induced changes in the reproductive tract that
resemble the alterations in sexual differentia-
tion produced by perinatal DES or E2. Both
prenatal and neonatal GEN treatments
resulted in precocious vaginal opening, and
neonatal treatments were associated with
reductions in serum progesterone at 50 days of
age and follicular abnormalities such as atretic
antral follicles and fewer corpora lutea (123).
Only two studies have directly examined
isoﬂavone inﬂuences on the breast in women
(Table 15). Chinese and Japanese women
had lower nipple aspirate ﬂuid volume, lower
mean levels of gross cystic disease fluid pro-
tein, fewer hyperplasic cells, and fewer atypi-
cal epithelial cells in their nipple aspirate
fluid than American women, an effect that
was postulated to be a consequence of con-
sumption of soy isoflavones (53). However,
supplementation of the diets of American
women with soy protein, providing GEN
and DAI doses of 0.6 and 0.4 mg/kg/day,
respectively, stimulated breast epithelial cell
proliferation and 2- to 6-fold increases in
nipple aspirate fluid volume in 29% of pre-
menopausal (PRE) women (53). Monthly
plasma collections suggested that E2 also was
erratically elevated. A second study exam-
ined the proliferation rate of breast epithe-
lium in biopsy samples from women with
benign or malignant breast disease treated
with and without a soy supplement provid-
ing an isoflavone dose of 0.75 mg/kg/day
(124). After 14 days of treatment, the prolif-
eration rate of the lobular epithelium and
PR expression were significantly increased
when day of menstrual cycle and patient age
were taken into account. These unexpected
results illustrate the difﬁculties of predicting
human responses and the need for careful
clinical trials. 
Table 14. Phytoestrogen inﬂuences on the human menstrual cycle.
Supplement Dose (mg/kg/day) Duration n Hormonal sampling Cycle length E2 Testosterone P4 LH Ref
Flax ENL, END ~0.09 3 cycles 18 Monthly; composite cycle Prolonged luteal  ↑ (98)
Soy GEN, DAI 0.75 1 month 6 Daily  Prolonged follicular ↑↓ (52)
GEN: 0.3 DAI: 0.4
Soy GEN, DAI 3  1 month 6 Cycle days 7 and 22 Prolonged 5/6, short 1/6 ↓↓ ↓ (99)
GEN: 1.5 DAI: 1.5
Soy GEN, DAI 1 6 months 24 Random No change ↑ (53)
GEN: 0.6; DAI:0.4
Soy GEN, DAI 1 3 cycles 14 Every other day No change ↓ (100) 
2 No change ↓ E1 uE2 uE1 (102)
Soy milk GEN, DAI 1.5 2 cycles 31 Prolonged E1 ↓ p = 0.07 (101)
Abbreviations: P4, progesterone; uE1, urinary estrone; uE2, urinary estradiol.
Table 15. Isoﬂavone actions in mammary tissue and breast cancer.
Species Focus Agent Dose (mg/kg/day) Age Effect Ref
Ovx mouse Mammary epithelium FRM 40 sc Adult Proliferation (111)
Ovx rat Mammary lobular alveolar structure GEN 36 orala Adult Maintained structure (112) 
Immature rat Mammary size GEN 500 sc Adult Increased weight (97)
Ovx long-tail macaque Mammary epithelium Soy isoﬂavone 10 oral Adult No effect (116)
Human Mammary epithelium Soy isoﬂavone 1 oral PRE Proliferation (53) 
Nipple aspirate ﬂuid ↑ Fluid
Human Lobular epithelium Soy isoﬂavone 0.75 oral PRE Proliferation; ↑ PR (124)
Rat DMBA-induced mammary cancer GEN + DAI GEN 2–8 DAI 1–3 oral PND 25–155 20–40% ↓ tumor number (108)
Rat MNU-induced mammary cancer GEN 3–8 ip PND 35–215 27% ↓ tumor number; p < 0.07  (109)
Rat MNU-induced mammary cancer DAI 3–8 ip PND 35–215  27% ↓ tumor number; p < 0.26 (109)
Rat DMBA-induced mammary cancer GEN 500 sc PND 16,18,20 50% ↓ tumor number (97)
Rat DMBA-induced mammary cancer GEN 500 sc PND 2,4,6 50% ↓ tumor number (110)
Rat Implanted tumor cells Soy extract (18 mg ip)  ↑ tumor growth (114)
Rat Implanted tumor cells GEN 11 orala PND 28 ↑ mammary & tumor size (115) 
Rat Spontaneous tumorigenesis ZLN 10 sc PND 7,14 ↑ tumor incidence (121)
PND, postnatal day. 
aEstimated from dietary concentration. 
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Prostate and Testes
Evidence for high expression of ERβ in the
prostate suggests that it could be an impor-
tant target for phytoestrogen action. There is
evidence for estrogenic action of isoflavones
in the prostate. Isoflavonoids induce c-fos
expression in the murine prostate at doses of
0.025–2.5 mg/kg/day sc (GEN) and 5
mg/kg/day (COM, DAI) (125,126). Ten
days of treatment with GEN (2.5 mg/kg/day
sc) induced neoplastic transformation in
neonatally estrogenized mice, whereas a sc
dose of 1.2 mg/kg/day had no effect (125).
On the other hand, rats maintained on a soy-
free diet for 11 weeks developed prostatitis in
the lateral lobe of the prostate, an inﬂamma-
tion that can be induced by estrogen (127),
suggesting that soy isoﬂavones might antago-
nize the actions of endogenous estrogens in
the prostate. A recent study provided evi-
dence for a suppressive effect of isoflavones
on the hypothalamic–pituitary–gonadal axis,
showing that 9 days of treatment with sc
GEN at a dose of 2.5 mg/kg/day reduced tes-
ticular and serum testosterone, pituitary LH
content, and prostate weight in adult male
mice (126). 
GEN inhibited the growth of prostate
cancer tissue in 3-dimensional histoculture at
concentrations of 4–37 µM (128), but dietary
doses of 0.07–0.3 mg/kg/day GEN had no
effect on the growth of matairesinol (MAT)
LyLu prostate cancer cells implanted sc in
male rats (129). Intraperitoneal doses of
0.1–0.4 mg/kg/day also had minimal effect
(129). However, a diet containing a high
isoﬂavone soy protein isolate reduced tumor
incidence and prolonged the latency to tumor
development in MNU-treated Lobund-
Wistar rats (130). 
There are no published tests of preventa-
tive actions of phytoestrogens in human
prostate cancer. However, a single clinical case
has been reported in which apoptosis typical of
high-estrogen therapy was seen in a man who
took 160 mg of phytoestrogen per day for 1
week prior to radical prostatectomy (131). 
Bone Density
Estrogen is required for maintenance of
normal bone density, and some phytoestro-
gens have been investigated as potential
estrogen replacement therapy in post-
menopausal women. Ipriﬂavone, (IPR; 7-iso-
propoxyisoflavone), an isoflavone derivative,
has been the phytoestrogen most studied as
a therapeutic agent in osteoporosis. Daily
oral doses of 3–10 mg/kg/day IPR prevent
bone turnover and loss in bone density in
women who are postmenopausal or who
have been treated with gonadotropin-
releasing hormone (GnRH) agonists
(132–134). These doses produce plasma
concentrations (135) similar to the in vitro
concentrations (≥ 100 nM) required for
inhibition of osteoclast differentiation (136)
and bone resorption (137). Much higher oral
doses (50–400 mg/kg/day) of IPR have been
required to prevent bone loss in ovariec-
tomized rats (138), doses that also produce
plasma concentrations similar to the effective
in vitro concentrations (139,140). COM also
inhibits bone resorption in vitro (141) and is
a more potent agent, preventing bone loss at
oral doses of 1–2 mg/kg/day (142,143).
Results with GEN, on the other hand, have
been inconsistent. No effect on bone density
is seen in ovariectomized rats with oral doses
of 0.1–30 mg/kg/day GEN (142), whereas
doses of 2 mg/kg/day (but not 6–20 mg/kg/
day) preserve bone density in ovariectomized
lactating rats (144). A dietary supplement
providing approximately 10 mg/kg/day
GEN, 17 mg/kg/day FRM, and 19 mg/kg/
day biochanin A also had no effect on bone
density (142). DAI, in contrast, actually stim-
ulates bone resorption in vitro at concentra-
tions of only 0.01–0.1 nM (145) but has not
been tested in vivo. DAI is one of the
metabolites of IPR, and its opposing effects
may help to explain why such high doses of
IPR are required to prevent bone loss.
The role of estrogen receptors in these
actions is unclear. Although both ERα and
ERβ are expressed in human (146) and rat
(147) osteoblasts, there is no convincing evi-
dence for either in osteoclasts (148), and pre-
osteoclastic cells have not been examined.
Unlike other isoﬂavonoids, IPR does not dis-
place E2 binding in MCF7 cells or induce
ERα-dependent gene transcription (149). IPR
enhances E2 binding to preosteoclasts, but its
binding to the same cells (Kd = 68 nM) is not
displaced by E2 (149). Moreover, IPR appears
to have minimal or no estrogen action on its
own, although it augments the estrogenic
effect of E2 and estrone (E1) on uterine weight
and thyroid calcitonin release (150). 
Cardiovascular Function
Reductions in serum cholesterol were
produced in ovariectomized rats by 4 days of
oral treatment with α-zearalanol (ZAL)
(ED50 = 0.2 mg/kg/day), COM (ED50 = 0.4
mg/kg/day), and GEN (ED50 = 0.5 mg/kg)
(142). One month of treatment with 100
mg/kg/day IPR also reduced serum choles-
terol in ovariectomized rats (151). A soy sup-
plement providing approximately 7
mg/kg/day GEN plus 3 mg/kg/day DAI to
ovariectomized female rhesus macaques with
diet-induced atherosclerosis produced free
plasma concentrations as high as 20 nM
GEN and 40 nM DAI (152,153). The
isoﬂavone diet improved a number of cardio-
vascular risk factors such as lower total
plasma cholesterol, elevated high-density
lipoprotein cholesterol, lowered arterial lipid
peroxidation, and enhanced dilator response
of atherosclerotic arteries (152–154). 
Five- to 12-week treatments with soy sup-
plements providing 0.7–1.5 mg/kg/day
isoﬂavones did not alter serum lipids in men
and women with average serum cholestrol
concentrations (86,155–157), although
reductions in LDL cholesterol have been
observed in hypercholesterolemic women fol-
lowing soy isoflavone treatment (158).
However, arterial compliance, a measure of
arterial elasticity, was improved in
menopausal women after 10 weeks of treat-
ment with 0.7–1.2 mg/kg/day clover
isoﬂavones (157). 
Hypothalamic and Pituitary Feedback
Several studies have examined the influence
of phytoestrogens on basal LH or LH release
(Table 16). In ovariectomized rats, a low
GEN dose (1 ng/kg iv) enhanced GnRH-
induced LH release, whereas higher doses
(1–10 µg/kg iv and 0.1–10 mg/kg iv) inhib-
ited LH release (159,160). Pretreatment with
GEN 8 mg/kg sc or ZLN (0.8–8 mg/kg sc)
did not inhibit tonic LH release, but these
doses did block GnRH-stimulated LH release
(161). However, oral doses of 0.1–10 mg/kg
GEN, administered by gavage, had no effect
on tonic LH (160). In rhesus macaques, ZLN
suppressed LH at sc doses of 5–14 µg/kg and
oral doses of 400 µg/kg (162). 
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Table 16. Phytoestrogen effects on anterior pituitary hormones.
Species Phytoestrogen Dose (mg/kg/day) Hormone Outcome Ref
Rhesus macaques ZNL 0.005–0.014 sc Plasma LH ↓ LH (162)
0.4 oral ↓ LH
Ovx rats ZNL 0.8–8 sc  Plasma LH No effect (161)
Ovx rats ZNL 0.8-8.0 sc GnRH-stimulated LH ↓ LH (161)
Ovx rats GEN 0.1–10 gavage Plasma LH No effect (161)
Ovx rats GEN 8 sc GnRH-stimulated LH ↓ LH (159) 
0.001–10 iv ↓ LH (160) 
1 ng/kg  ↑ LH (161)
Ovx mice GEN 40 mg/kg sc Plasma PRL ↑ PRL (211)
Ovx rats GEN 36 mg/kg orala Plasma PRL ↑ PRL (112)
Ovx rats  GEN 36 mg/kg orala E2-stimulated PRL No effect (112)
Postmenopausal women Soy isoﬂavones 0.7–1 Periovulatory LH ↓ LH (52,100)
Postmenopausal women Soy isoﬂavones 0.7–1 LH response to GnRH ↓ LH (163)
aEstimated from dietary concentration.
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There is some evidence that phyto-
estrogens can inﬂuence human LH secretion.
Soy supplements providing 0.7–1 mg/kg/day
isoflavones reduced mid-cycle LH (52,100),
and suppression of the LH response to GnRH
was observed in postmenopausal women with
a similar supplement (163). ZLN suppressed
LH secretion in postmenopausal women at
similar dietary doses (0.4 mg/kg/day) (164).
Developmental Effects
The developmental actions of phytoestrogens
have been studied mostly in rats and inter-
preted to have implications for human health.
The impact of phytoestrogens on human fetal
development is unclear, but the results of
DES exposure have shown that early estrogen
exposure can have profound effects. Although
the immediately observable effects are limited
in rodents, prenatal or neonatal exposure to
phytoestrogens results in altered prepubertal
or adult morphology and/or function in the
uterus, vagina, ovary, breast, pituitary, and
hypothalamus (Table 17). Reduced respon-
siveness to estrogen is apparent in the uterus,
breast, and prostate, whereas symptoms of
hyperestrogenization are apparent in the vagi-
nal tract. Although the phytoestrogens vary in
effective dose range and end points effected,
COM, GEN, EQL, and ZLN all appear to
exhibit some of the developmental actions
that have been reported for other more
potent nonsteroidal estrogens like DES.
Active sc doses in neonates range from 0.005
to 50 mg/kg/day for COM and 10 to 500
mg/kg/day for GEN and ZLN. Effective
maternal doses range from 0.2 to 17
mg/kg/day for both oral and sc doses.
Although many of these doses are quite high,
reports of effects at rather low doses, particu-
larly in rat dams, argue for a fuller examina-
tion of dose–response relationships. 
Summary and Conclusions
Binding studies using purified receptor pro-
teins show that the isoflavonoid phytoestro-
gens are high-affinity ligands for ERs,
especially ERβ. In whole-cell assays, however,
their RP is signiﬁcantly lower, probably as a
result of interactions with binding proteins
and other as yet unidentiﬁed factors. As with
other endocrine-active compounds, a wide
variety of enzymatic actions have been
reported for phytoestrogens. However, many
of these in vitro actions require concentrations
higher than those normally seen in plasma. 
In vivo data show that phytoestrogens
have a wide range of biologic effects at doses
and plasma concentrations seen with normal
human diets. Significant in vivo responses
have been observed in animal and human
tests for bone, breast, ovary, pituitary, vascu-
lature, prostate, and serum lipids. These
actions represent a broader range of tissues
and processes, including many beneﬁcial out-
comes, than the end points generally used to
assess health risks posed by exposure to
endocrine-active compounds (5). Reports of
ERβ in many of the tissues that appear to be
responsive to phytoestrogens are intriguing,
but currently there are not sufﬁcient data to
assess the relative sensitivity of different end
points. For some of these end points, similar
responses to phytoestrogens have been
reported in humans and animal models,
although there are currently insufﬁcient data
to carry out detailed comparisons. 
The biphasic actions of phytoestrogens
complicate the process of assigning lowest
observed adverse effect levels. In this case, the
actions presumed to be more beneﬁcial (e.g.,
antiproliferative actions) occur at higher in
vitro concentrations (micromolar) than the
proliferative actions presumed to be more
harmful (nanomolar concentrations). This
pattern would predict that higher, rather than
lower, doses would be more beneﬁcial in vivo.
Moreover, human plasma and tissue concen-
trations are primarily in the nanomolar range,
suggesting that proliferative effects should be
more likely to be observed.
The in vivo situation is more complex,
however. Oral soy isoflavone doses of 3–8
mg/kg/day delay the development of car-
cinogen-induced breast tumors in rats,
whereas GEN doses reported to stimulate
growth of breast and uterine epithelia range
from 10 to 36 mg/kg/day. However, a
recent study has shown that oral GEN doses
as low as 11 mg/kg/day enhance the growth
of implanted mammary tumors as well as
the mammary gland. Moreover, two studies
have reported proliferation of breast epithe-
lium in women with oral soy isoflavone
doses of 0.7–1 mg/kg/day. The similarity of
Table 17. Developmental effects of phytoestrogens and mycoestrogens in rodents.
Tissue Species Life stage Phytoestrogen Dose (mg/kg/day) Effect Ref
Uterus Rat Neonatal COM 1–10 sc Uterine and gland growth, later ↓ weight, ER (212,213)
COM 25–50 sc Squamous metaplasia
EQL 10–100 sc Later ↓ weight
ZNL 1–100 sc Uterine growth, later?
Vagina Mouse Neonatal COM 0.005–50 sc Persistent corniﬁcation (214,215)
COM 25–50 sc Cervicovaginal adenosis
Rat Prenatal GEN 17 sc - dams Delayed vaginal opening, normal cycles
Ovary Mouse Neonatal COM 10 sc Polyovular follicles (215) 
Rat Neonatal GEN 500 sc Atretic antral follicles, ↓ corpora lutea (123,216)
Prenatal, neonatal GEN 0.2 oral - dams Atretic follicles, cystic rete ovarii
Breast Rat Neonatal GEN 500 sc Increased terminal duct differentiatiion (123)
ZNL 10 sc Spontaneous tumors
Anogenital Rat Prenatal GEN 17 sc - dams Decreased distance in males (214)
Prostate Mouse Neonatal DES COM, DAI  7 sc - adults Increased c-fos (217)
Neonatal DES 13% Soy diet [9.4 µM excreted/day] Prevention of DES lesions
Pituitary Rat Neonatal COM 0.01–1 sc ↑ Basal LH in females (218,219)
COM 1 sc ↓ GnRH-stimulated LH
GEN 10 sc ↑ GnRH-stimulated LH
GEN 100 sc ↓ GnRH-stimulated LH, ↓ basal LH
ZNL 10–100 sc ↓ GnRH-stimulated LH, ↓ basal LH
Hypothalamus Rat Neonatal COM 7 oral - dams Premature anovulation, abnormal sexual  (220)
behavior in males
SDN-POA Rat Neonatal COM 0.01–1 sc No effect (218,219)
GEN 100 sc No effect (10), enlarged in females (100)
ZNL 100 sc Enlarged in females, 10: no effect
SDN-PDA, sexually dimorphic nucleus of preoptic area.
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reported proliferative and antiproliferative
doses illustrates the need for fuller examination
of dose–response relationships and multiple
end points in assessing phytoestrogen actions. 
The lowest effective concentrations in
animals have been reported for induction of
c-fos in the prostate and regulation of choles-
terol, testosterone, and LH. The low effective
doses reported for c-fos suggest that molecular
or biochemical end points may be more sensi-
tive indices of phytoestrogen response than
the morphologic or functional end points
commonly tested. The low doses reported for
phytoestrogen effects on hormonal secretion
suggest that steroidogenesis and the hypothal-
amic–pituitary–gonadal axis are important
loci of phytoestrogen actions. However, these
inferences must be tentative because good
dose–response data are not available for many
end points and many of the doses may not be
the lowest active doses. 
The available data indicate that phytoe-
strogens are biologically active in humans at
dietary doses of 0.4–10 mg/kg/day (Table
18). The active isoﬂavone doses are similar to
the daily intakes estimated for adults consum-
ing soy-rich Asian diets, which may be pri-
marily a consequence of attempts to test the
hypothesized health benefits of Asian diets.
Few human studies have attempted to test a
range of doses. Moreover, all of the human
studies have used isoﬂavone mixtures present
in extracts of soy or red clover, making it dif-
ﬁcult to assess the contributions and activity
of individual isoﬂavones. This issue is particu-
larly important in light of the in vitro and in
vivo data showing that GEN and DAI some-
times exhibit opposing effects. Moreover,
most studies have relied on manufacturer’s
data on isoflavone content to estimate daily
intake, so the actual doses used may vary even
in studies using the same soy supplements. 
The doses reported to be active in
humans are lower than the doses generally
reported to be active in rodents (10–100
mg/kg/day), although some studies have
reported rodent responses at lower doses
(0.005–0.2 mg/kg/day). However, the avail-
able estimates of bioavailability and peak
plasma levels in rodents and humans are more
similar. More studies are needed to determine
whether lower doses are effective in rodents
and humans and whether bioactive doses are
associated with similar plasma levels in
humans and animal models. 
These comparisons illustrate the rich data-
base available on phytoestrogen actions, mech-
anisms, and metabolism and highlight gaps
and discrepancies in the dataset. These ﬁnd-
ings demonstrate some of the complexities of
extrapolating across assays, species, and com-
pounds. As dietary components, phytoestro-
gens generally have been treated and tested
like nutrients rather than pharmacologic
agents. As a result, researchers have investi-
gated a number of beneficial properties that
would be overlooked in toxicologic studies but
also have failed to anticipate some potentially
adverse properties. There is currently very little
information on the balance of effects in indi-
viduals, data that ultimately will be required in
order to assess the wisdom of phytoestrogen
consumption. More detailed pharmacokinetic
data are required to more accurately evaluate
the reliability of extrapolating from in vitro to
in vivo studies or across species. Such compar-
isons are likely to provide new insights into the
evaluation of other exogenous estrogens. 
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